Pharmaceutical Technology

FEBRUARY 20, 2023

Different approaches that are studied include antisense oligonucleotides (ASOs), and gene therapies, which are in early clinical trials. Other lines of research look at the genetic overlap between FTD and amyotrophic lateral sclerosis (ALS), which could be used in the development of treatments for both conditions.

Development 246

Development Gene Therapy Protein Gene 246

Pharmaceutical Technology

MAY 26, 2023

HanAll Biopharma and Daewoong Pharmaceutical have entered into a co-development deal with NurrOn Pharmaceuticals to develop therapy for Parkinson’s disease (PD) and other neurodegenerative disorders. They will help to progress ATH-399A towards a Phase I trial.

Development 130

Development Clinical Trials Clinical Trials Protein 130

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 52

Trials Clinical Trials Clinical Trials Protein 52

Pharmaceutical Technology

JANUARY 25, 2023

A researchers’ team from the University of Texas at San Antonio’s (UTSA) Department of Chemistry and its partners are developing compounds to treat Glioblastoma multiforme (GBM) tumours. The new compounds imitate the sex hormone estrogen activity on a cell protein known as estrogen receptor-beta (ER-beta), which is known to suppress cancer.

Development 246

Development Research Hormones Gene 246

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI. TRACTION is a part of the therapeutics discovery division of MD Anderson.

Development 130

Development Clinical Trials Clinical Trials Protein 130

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

XTalks

JANUARY 29, 2021

This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. This means that sponsors are having to fork out for these blockbuster products in order to run their trials more often.

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

JUNE 20, 2023

Developed using pharmaceutical company GSK’s pandemic adjuvant, the vaccine targets the receptor-binding domain of the SARS-CoV-2 spike protein. The vaccine is based on recombinant protein vaccine technology and is suitable for storage between 2°C and 8°C.

Vaccination 363

Vaccination Vaccine Protein Clinical Trials 363

Drug Discovery World

AUGUST 9, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T cell therapy.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Licensing 52

Drug Discovery World

JUNE 28, 2023

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has completed enrolment and initial dosing in its Phase I clinical vaccine trial in older adults. The trial is taking place at CEVAC (Centre for Vaccinology), Ghent University, Belgium.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Vaccination 52

pharmaphorum

MARCH 24, 2021

Pfizer has begun clinical development of an antiviral pill against COVID-19, which could be prescribed to patients at the first sign of infection. PF-07321332 is a protease inhibitor, which has been able to block replication of the SARS-CoV-2 coronavirus in preclinical trials as well as other coronaviruses.

Clinical Trials 119

Clinical Trials Clinical Trials Trials Vaccination 119

pharmaphorum

JANUARY 18, 2022

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. Vaccitech and the Ludwig Institute are providing the drug while the Centre manages the trial and provides funding.

Clinical Trials 64

Clinical Trials Clinical Trials Trials Vaccination 64

Pharmaceutical Technology

APRIL 26, 2023

Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.

Clinical Development 147

Clinical Development Development Clinical Trials Clinical Trials 147

Pharmaceutical Technology

DECEMBER 7, 2022

Last week, the quest for an effective Alzheimer’s disease therapy received a notable fillip at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022, with new data on Eisai’s disease-modifying therapy lecanemab. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals.

Development 264

Development Drugs Clinical Trials Clinical Trials 264

Pharmaceutical Technology

DECEMBER 7, 2022

Last week, the quest for an effective Alzheimer’s disease therapy received a notable fillip at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022, with new data on Eisai’s disease-modifying therapy lecanemab. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals.

Development 246

Development Drugs Clinical Trials Clinical Trials 246

XTalks

NOVEMBER 7, 2022

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. How personalized, targeted assays can be developed to detect somatic mutations from cfDNA. “A

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. SL-172154 entered clinical trials in mid-2020, following promising preclinical results.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Pharmaceutical Technology

OCTOBER 20, 2022

PIC Therapeutics has raised $35m in a Series A funding round led by OrbiMed to develop therapies for drug-resistant breast cancer. The company will utilise the Series A funds to progress its small molecule drug presently in development into first-in-human clinical trials for advanced metastatic breast cancer.

Development 130

Development Drugs Protein Life Science 130

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

APRIL 22, 2022

Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

BioPharma Reporter

SEPTEMBER 3, 2020

Sanofi and GSK today start the Phase 1/2 clinical trial for their COVID-19 adjuvanted recombinant protein-based vaccine candidate.

Clinical Trials 83

Clinical Trials Clinical Trials Vaccination Vaccine 83

Drug Discovery World

FEBRUARY 27, 2024

Arvinas has commenced dosing in the Phase I clinical trial of ARV-102, its first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. The post First PROTAC degrader for neurodegenerative disease enters trials appeared first on Drug Discovery World (DDW).

Trials 52

Trials Protein Clinical Trials Clinical Trials 52

Scienmag

NOVEMBER 12, 2020

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

Immune Response 75

Immune Response Protein Clinical Trials Clinical Trials 75

pharmaphorum

NOVEMBER 4, 2020

It may not be appropriate to use the word ‘failure’ when summarising the utility of clinical trials in the search for a curative or preventative treatment for disease. Most of the trials are underpowered to demonstrate efficacy on mortality and long-term consequences of the disease.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Vaccination 105

Pharmaceutical Technology

JUNE 24, 2022

The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain. Developed utilising Novavax’s recombinant nanoparticle technology to generate antigen obtained from the coronavirus spike (S) protein, the vaccine is also formulated with the company’s saponin-based Matrix-M adjuvant.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Pharmaceutical Technology

SEPTEMBER 7, 2022

A recombinant replication-deficient adenovirus vectored vaccine, iNCOVACC has a prefusion stabilised spike protein and is claimed to be the first intranasal vaccine globally to obtain primary two-dose schedule approvals. The nasal delivery system was created and developed to be cost-efficient in low- and middle-income countries.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

pharmaphorum

MARCH 12, 2021

Sanofi and Translate BIO have begun a clinical trial of their potential mRNA COVID-19 shot, as the French pharma struggles to keep pace with rivals despite its background in vaccines. A joint development team is working on a -20C storage temperature for late-stage clinical development and at launch.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Vaccination 52

Pharmaceutical Technology

JULY 21, 2022

The company received fast-track designation from the US Food and Drug Administration (FDA) for the eltanexor development programme as a single agent to treat relapsed or refractory intermediate, high or very high-risk MDS patients. Eltanexor is a new oral selective inhibitor of nuclear export (SINE) compound.

Clinical Trials 264

Clinical Trials Clinical Trials Protein Production 264

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 These results came from data from Novavax’s Phase III UK trial where B.1.117

Protein 97

Protein Vaccination Vaccine Trials 97

XTalks

DECEMBER 12, 2023

The world of neuroscience trials is rapidly evolving, presenting new challenges and opportunities for researchers and clinicians. The worldwide market for neurology clinical trials stood at a valuation of $5.24 There is currently a heightened emphasis on imaging and liquid biomarkers in neuroscience clinical trials.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

XTalks

FEBRUARY 19, 2024

The study compared the immune responses evoked by Moderna’s mRNA vaccine to those generated by a previous vaccine candidate, namely, the MF59-adjuvanted glycoprotein B (gB) proten subunit vaccine (gB/MF59) developed by Sanofi. However, the development of an effective vaccine that can target CMV infection has been extremely challenging.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

BioPharma Reporter

DECEMBER 11, 2020

Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.

Immune Response 105

Immune Response Vaccination Vaccine Trials 105

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2023

Scientists have developed a new tool for determining the age of eye cells without sampling regenerative tissue, which could make treatments for eye disease more personalized and better targeted. Almost 6,000 proteins detected in the fluid could be traced […]

Protein 193

Protein Scientist Research Development 193

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours.

Development 130

Development Research Antibody Engineer 130